Partner with the Leaders Building Medtech

InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics. Visit website.

The Surgical-Fiberlcok technology functions like a surgical “sewing” machine, mechanically “interlocking” the medical patch fibers into soft tissue, allowing the surgeon to attach patches in an easier, faster, and more reliable way for various clinical applications for soft-tissue repair and augmentation. The enabling device for this technology, called FiberLocker® System, received FDA clearance for rotator cuff reinforcement in December 2024. Visit website.

Description coming soon. Visit website.

Onera Health is advancing sleep diagnostics through its patch-based technology designed for clinical and at-home use. The company’s solutions provide comprehensive sleep data to physicians, helping optimize care for patients with sleep-related conditions. By enabling more accessible and efficient testing, Onera supports improved outcomes while reducing overall healthcare costs. Visit website.

Lemonex is a clinical-stage biotechnology company developing thermostable RNA vaccines and gene therapeutics using its proprietary DegradaBALL® drug delivery system. DegradaBALL® is a non-viral, porous nanoparticle platform that enables room-temperature storage and reduces systemic side effects compared to conventional lipid nanoparticles. The company is partnered with CEPI to support pandemic preparedness through improved mRNA delivery. Lemonex’s technology aims to broaden global access to RNA medicines by improving stability, safety, and ease of administration.   Visit website.

LiveMetric develops a wrist-worn wearable device for continuous, calibration-free blood pressure monitoring. The FDA- and CE-cleared system captures arterial pressure waveforms at 100Hz, enabling real-time insights into cardiac output, heart rate, and stroke volume. Designed for remote monitoring and long-term cardiovascular care, the device provides ICU-level data without the need for traditional cuffs. LiveMetric supports scalable access to heart health information for patients, providers, and healthcare systems. Visit website.

Calla Lily Clinical Care is a women’s health-focused company pioneering the proprietary Callavid® platform for intravaginal drug delivery. Its first application targets IVF treatments, and will also position Callavid® as the world’s first drug–device combination product specifically aimed at miscarriage prevention.  Future indications include gynecological cancers and the delivery of live biotherapeutic products (LBPs) to reduce reliance on antibiotics and help combat antimicrobial resistance (AMR).  Calla Lily is redefining drug delivery in women’s health with precision, patient comfort, and global impact in mind.  Visit website.

Medulla Pro develops technology to support guided needle insertion procedures, with the goal of improving accuracy and reducing complications. The company’s solutions are designed for use in lumbar puncture and nerve block procedures, offering enhanced precision for clinicians and better outcomes for patients. Medulla Pro is focused on making guided procedures the standard of care through the application of advanced engineering. Visit website.

Neurosom™ is developing medical devices that integrate real-time sleep assessment with personalized therapy to support restorative health. The company’s Sleep WISP system is a wearable headband that uses EEG and machine learning to monitor sleep cycles and apply painless electrical stimulation to promote sleep onset and enhance deep sleep. Designed for home use, the system enables users to engage in sleep therapy without clinical oversight. Neurosom™ aims to advance the field of sleep through non-invasive, technology-driven solutions. Visit website.

Accure Medical is revolutionizing dermatology with the Accure Laser System, the first 1726nm platform to achieve both CE Mark certification and FDA clearance for the long-term treatment of mild to severe inflammatory acne vulgaris. Leveraging its patented treat-to-temperature technology, the system ensures consistent, safe, and effective results for all skin types. With rapid adoption across the US, Europe, Asia, and the Middle East, Accure is addressing a significant global need with its groundbreaking solution for acne treatment. Visit website.

VeinTech is an Australian medical technology company developing solutions to improve the accuracy and efficiency of intravenous (IV) cannulation. The company’s VeinWise System uses patented ultrasound-based technology to visualize vein pathways at depth, addressing long-standing limitations of the traditional landmark technique. Designed for ease of use and portability, the system supports clinicians in reducing insertion failures while enhancing patient comfort and clinical workflow. VeinTech’s approach aims to improve outcomes across healthcare settings by reducing complications and associated costs. Visit website.

TendonPlus Medical is developing a device designed to prevent sutures from cutting through tendon tissue, a common cause of rotator cuff repair failure. By reducing suture-induced tearing, the technology aims to lower post-operative revision rates and improve surgical outcomes. With an estimated 300,000 rotator cuff procedures performed annually in the U.S. and failure rates reaching up to 40% within a year, the need for improved tendon repair solutions is significant. TendonPlus is a portfolio company of Trendlines Medical Singapore. Visit website.

PURMX Therapeutics is developing novel nucleic acid medicines using proprietary small RNA-based technologies designed to modulate multiple gene targets. The company’s lead candidate, MIRX002, is a microRNA-based therapy for malignant pleural mesothelioma, currently being evaluated in investigator-initiated clinical trials at Hiroshima University Hospital. PURMX has also initiated a sponsor-led trial in Japan for head and neck squamous cell carcinoma (HNSCC). The company is preparing for global Phase 1/2 trials to advance both indications. Visit website.